Alligator Bioscience publishes financial calendar for 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2026: Deadline for Alligato ...
Alligator Bioscience enters into additional subscription undertakings and top guarantee commitments for the upcoming rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces publication of REACtiVe-2 Phase 1 trial data in Nature Communications
Lund, Sweden, 1 December 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the publication of a peer-reviewed arti ...
Alligator Bioscience publishes prospectus in connection with rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 25 November 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follo ...
Alligator Bioscience announces final terms of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience presents new data on mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting
Lund, Sweden – 5 November 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developi ...
Nomination Committee appointed in respect of AGM 2026 in Alligator Bioscience AB
Lund, Sweden, 3 November 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumo ...
Alligator Bioscience AB reports financial results for Q3 2025 and provides a business update
Upcoming rights issue of approx. SEK 120 million (gross), providing 6–9 months of financial runway during 2026, announced 22 October S ...